107 - Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal Antibiotic

Rapid Fire Presenter(s)

• 

  Alireza Shamaei Tousi, PhD (he/him/his)

  Principal Clinical Scientist
  Debiopharm International
  Lausanne, Vaud, Switzerland

Co-Author(s)

• MM

  Moritz Marquardt, n/a

  Debiopharm International
  Lausanne, Vaud, Switzerland
• AM

  Annick Menetrey, n/a

  Debiopharm International
  Lausanne, Vaud, Switzerland
• JN

  Justyna Nowakowska, n/a

  Debiopharm International
  Lausanne, Vaud, Switzerland
• JD

  Justine Dao, n/a

  Debiopharm International
  Lausanne, Vaud, Switzerland
• DC

  David Cameron, PhD

  Senior Scientist
  Debiopharm International
  Lausanne, Vaud, Switzerland
• CC

  Charlotte Catala-Goldschmidt, n/a

  Debiopharm International
  Lausanne, Vaud, Switzerland
• RC

  Ricardo Chaves, n/a

  Debiopharm International
  Lausanne, Vaud, Switzerland